샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795370

세계의 줄기세포 제대혈 시장

Stem Cell Umbilical Cord Blood
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 127 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

줄기세포 제대혈 세계 시장은 2030년까지 77억 달러에 달할 전망

2024년에 26억 달러로 추정되는 줄기세포 제대혈 세계 시장은 2024년부터 2030년까지 CAGR 19.9%로 성장하여 2030년에는 77억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 의약품 최종사용은 CAGR 21.5%를 기록하며 분석 기간 종료시에는 42억 달러에 달할 것으로 예측됩니다. 연구기관 최종사용 분야의 성장률은 분석 기간 동안 CAGR 17.2%로 추정됩니다.

미국 시장은 6억 8,350만 달러로 추정, 중국은 CAGR 18.7%로 성장 예측

미국의 줄기세포 제대혈 시장은 2024년에 6억 8,350만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 12억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 18.7%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 18.5%와 17.1%로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.4%로 성장할 것으로 예측됩니다.

세계의 줄기세포 제대혈 시장 - 주요 동향과 촉진요인 정리

제대혈 줄기세포에 대한 관심을 불러일으키는 것은 무엇일까?

조혈전구세포와 간엽전구세포를 풍부하게 함유하고 있는 제대혈 줄기세포는 중요한 재생의료 도구로 부상하고 있습니다. 그 용도는 혈액 질환, 면역 결핍, 일부 대사성 질환의 치료에 이르기까지 다양합니다. 출생 시 탯줄 혈액을 채취하여 은행에 보관하는 것은 가족에게 적극적인 건강 관리 옵션이 되어 자가 또는 동종 이식의 가능성을 제공하고 있습니다. 임상의들은 제대혈은 거부반응이 적고, 비침습적이며 배아줄기세포에 대한 논란을 피할 수 있어 윤리적으로도 용이하다고 말합니다. 공공 제대혈 은행과 민간 제대혈 보관 서비스는 산부인과 센터와 협력하여 수집 프로토콜을 간소화하고 있습니다. 또한, 제대혈은 신경학, 자가면역질환, 조직수복 등 새로운 치료법을 위한 줄기세포 공급원으로 연구되고 있어 기존 혈액학의 틀을 넘어선 확장된 파이프라인을 보여주고 있습니다.

탯줄 혈액의 채취와 보존은 기술 발전에 따라 개선되고 있는 것일까?

DMSO가 없는 동결 보호제, 자동 제어된 동결 속도, 최적화된 보존 시스템 등 첨단 동결보존 솔루션은 해동 후 세포의 생존율을 높입니다. 하이스루풋 프로세싱 플랫폼은 표준화된 용적 감소, 적혈구 제거, CD34+ 농축을 가능하게 합니다. 디지털 추적은 채취 키트에서 보관소까지 엔드 투 엔드 샘플 추적성을 보장하고, 은행이 규제 감사 및 인증 기준을 준수할 수 있도록 지원합니다. 전자 의료 기록과의 통합을 통해 의사는 가용성, 적합성 기준, 조직 적합성 보고서를 신속하게 확인할 수 있어 이식 전 의사결정을 용이하게 하고 결과를 개선할 수 있습니다.

왜 가족과 병원은 제대혈 은행을 받아들이는가?

소아 만성질환 및 유전질환의 증가로 예방적 안전장치로서 제대혈은행에 대한 관심이 높아지고 있습니다. 부모들은 은행에 보관된 제대혈을 자신의 자녀와 가까운 친척들에게 매우 가치 있는 생물학적 자산으로 여기고 있습니다. 민관 파트너십을 통한 뱅킹 모델의 발전은 경제적으로 여유가 없는 가족도 조사 접근이 가능한 공공 뱅킹을 지원할 수 있게함으로써 형평성을 촉진하고 있습니다. 임상의와 이식센터는 세포 수가 많고 항원 적합성이 가장 좋은 제대혈 단위를 선호합니다. 공급업체들이 지원 활동과 교육 프로그램을 확대함에 따라 제대혈의 치료 가능성에 대한 인식이 높아지고 있습니다.

제대혈 줄기세포 시장의 성장 원동력은?

줄기세포 제대혈 시장의 성장은 첨단 저온 기술, 치료 사용 사례의 확대, 의료 정책의 발전과 관련된 여러 요인에 의해 주도되고 있습니다. FDA가 승인한 20개 이상의 치료법과 신경, 자가면역, 대사 적응증에 대한 임상시험의 증가로 수요가 확대되고 있습니다. 강화된 냉동보존 기술은 장기적인 생존성과 유효성을 보장하고, 환자의 예후를 개선합니다. 유럽, 아시아태평양, 북미 등의 지역에서는 정부의 장려책과 보험 적용 정책으로 인해 뱅킹 도입이 활발하게 이루어지고 있습니다. 분만센터, 은행, 연구기관 간의 파트너십은 수집 물류를 간소화하고 있습니다. 마지막으로, 제대혈의 치료적 가치에 대한 사회적 인식의 증가와 인증된 제대혈 은행에 대한 브랜드 신뢰가 민간 및 공공 보관 모두에 박차를 가하고 있습니다.

부문

최종사용자(의약품 최종사용자, 조사 최종사용자, 병원 최종사용자, 바이오뱅크 최종사용자)

조사 대상 기업 사례

  • AlphaCord LLC
  • Americord Registry
  • ATCC(American Type Culture Collection)
  • Celularity
  • Cells4Life Group LLP
  • CellResearch Corporation
  • Cord Blood Registry(CBR)
  • Cord Blood Registry(ViaCord, PerkinElmer)
  • CordforLife
  • Cordlife Group Ltd
  • Cryo-Cell International
  • FamiCord Group
  • Global Cord Blood Corporation
  • LifeCell International
  • MiracleCord
  • NECBB(New England Cord Blood Bank)
  • PerkinElmer(ViaCord)
  • Precision Cellular Storage/Virgin Health Bank
  • Relicord
  • StemCyte

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSM 25.09.01

Global Stem Cell Umbilical Cord Blood Market to Reach US$7.7 Billion by 2030

The global market for Stem Cell Umbilical Cord Blood estimated at US$2.6 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2024-2030. Pharmaceuticals End-Use, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Research Institutes End-Use segment is estimated at 17.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$683.5 Million While China is Forecast to Grow at 18.7% CAGR

The Stem Cell Umbilical Cord Blood market in the U.S. is estimated at US$683.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.5% and 17.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global Stem Cell Umbilical Cord Blood Market - Key Trends & Drivers Summarized

What’s Driving Interest in Umbilical Cord Blood Stem Cells?

Umbilical cord blood stem cells, rich in hematopoietic and mesenchymal progenitors, have emerged as vital regenerative medicine tools. Their applications span treatments for blood disorders, immune deficiencies, and some metabolic diseases. Collecting and banking cord blood at birth has become a proactive healthcare choice for families, offering a potential autologous or allogeneic transplant source. Clinicians rely on the cells’ lower rejection rates and ethical ease-as collection is non-invasive and avoids embryonic stem cell controversies. Public cord blood banks and private storage services are collaborating with obstetric centers to simplify collection protocols. Additionally, cord blood is being explored as a stem cell source for emerging therapies in neurology, autoimmune disorders, and tissue repair, indicating an expansion pipeline beyond traditional hematology.

Are Technological Improvements Enhancing Collection and Storage?

Advanced cryopreservation solutions- using DMSO-free cryoprotectants, automated controlled-rate freezing, and optimized storage systems-are increasing cell viability post-thaw. High-throughput processing platforms are enabling standardized volume reduction, red blood cell depletion, and CD34+ enrichment. Digital tracking ensures end-to-end sample traceability-from collection kit to storage vault-helping banks comply with regulatory audits and accreditation standards. Integration with electronic health records allows physicians to quickly verify availability, matching criteria, and histocompatibility reports-facilitating pre-transplant decision-making and improving outcomes.

Why Are Families and Clinics Embracing Cord Blood Banking?

The rise in chronic and genetic pediatric disorders has elevated interest in cord blood banking as a preventative safeguard. Parents view banked cord blood as a high-value biological asset for their child and immediate family. Advances in public-private partnership banking models allow families without means to support research-accessible public banking, promoting equity. Clinicians and transplant centers prioritize cord blood units with high cell counts and optimal antigen matching. As suppliers expand outreach and educational programs, awareness around banked cord blood’s therapeutic potential is increasing.

What’s Powering the Growth in the Cord Blood Stem Cell Market?

The growth in the stem cell umbilical cord blood market is driven by several factors related to advanced cryogenic technology, expanded therapeutic use cases, and evolving healthcare policies. Over two dozen FDA-approved therapies and increasing clinical trials for neurological, autoimmune, and metabolic indications are broadening demand. Enhanced cryopreservation techniques ensure long-term viability and efficacy, enhancing patient outcomes. Government incentives and insurance coverage policies in regions like Europe, Asia-Pacific, and North America are supporting banking adoption. Partnerships between birthing centers, banks, and research institutions are streamlining collection logistics. Finally, growing public awareness of cord blood’s therapeutic value and branding trust in accredited banks are fueling both private and public storage.

SCOPE OF STUDY:

The report analyzes the Stem Cell Umbilical Cord Blood market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use, Biobanks End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • AlphaCord LLC
  • Americord Registry
  • ATCC (American Type Culture Collection)
  • Celularity
  • Cells4Life Group LLP
  • CellResearch Corporation
  • Cord Blood Registry (CBR)
  • Cord Blood Registry (ViaCord, PerkinElmer)
  • CordforLife
  • Cordlife Group Ltd
  • Cryo-Cell International
  • FamiCord Group
  • Global Cord Blood Corporation
  • LifeCell International
  • MiracleCord
  • NECBB (New England Cord Blood Bank)
  • PerkinElmer (ViaCord)
  • Precision Cellular Storage / Virgin Health Bank
  • Relicord
  • StemCyte

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Stem Cell Umbilical Cord Blood - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Blood-Related Disorders Drives Adoption of Cord Blood Stem Cell Therapies
    • Increased Use in Transplant Procedures Strengthens Clinical Relevance of Banked Cord Blood
    • Government Support and Public Banking Initiatives Expand Access and Awareness
    • Technological Advancements in Cryopreservation Improve Cell Viability and Storage Duration
    • Expansion of Private Cord Blood Banks Boosts Consumer Participation and Industry Funding
    • Regenerative Medicine Developments Propel Use of Cord Blood in Non-Hematologic Applications
    • Standardization of Regulatory Frameworks Enhances Global Market Credibility
    • Surge in Stem Cell Clinical Trials Broadens Therapeutic Indications and Market Potential
    • Awareness Campaigns and Obstetrician Recommendations Increase Collection Rates
    • Strategic Collaborations With Hospitals Facilitate On-Site Collection Services
    • Increased Investments in Stem Cell Research Strengthen Commercial Viability
    • Innovation in Cell Expansion and Differentiation Techniques Enhances Utility of Stored Cells
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stem Cell Umbilical Cord Blood Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stem Cell Umbilical Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Stem Cell Umbilical Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pharmaceuticals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pharmaceuticals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pharmaceuticals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biobanks End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Biobanks End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Biobanks End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: China 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Stem Cell Umbilical Cord Blood by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: France 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Rest of World 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제